FDA approves new blood cancer treatment from Pfizer

The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy.Pfizer plans to launch the drug, Daurismo, in the United States by early December with a monthly list price of $16,925, a Pfizer spokeswoman told Reuters.Daurismo was approved for use in adults with acute myeloid leukemia (AML) aged 75 or older or those who have certain health conditions prior to receiving their diagnosis, for whom int